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Abstract
Objective. To determine if folic acid supplementation improves vascular
function (brachial artery flow-mediated dilation [FMD]) in professional dancers
with known endothelial dysfunction.
Design. Prospective cross-sectional study.
Setting. Academic institution in the Midwestern United States.
Subjects. Twenty-two professional ballet dancers volunteered for this study.
Main Outcome Measures. Subjects completed a 3-day food record to
determine caloric and micronutrient intake. Menstrual status was determined
by interview and questionnaire. Endothelial function was determined as flowinduced vasodilation measured by high-frequency ultrasound of the brachial
artery. A change in brachial diameter of <5% to hyperemic flow stimulus was
defined a priori as endothelial dysfunction. Subjects with abnormal FMD took
10 mg of folic acid daily for 4 weeks, and FMD testing was then repeated.
Serum whole blood was measured for folic acid levels before and after
supplementation.
Results. Sixty-four percent of dancers (n = 14) had abnormal brachial artery
FMD (<5%) (mean ± standard deviation, 2.9% ± 1.5%). After 4 weeks of
folic acid supplementation (10 mg/day), FMD improved in all the subjects
(7.1% ± 2.3%; P < .0001).
Conclusions. This study reveals that vascular endothelial function improves
in dancers after supplementation with folic acid (10 mg/day) for at least 4
weeks. This finding may have clinically important implications for future
cardiovascular disease risk prevention.

Introduction
Previous studies have shown that amenorrheic athletes have
evidence of impaired vascular function manifested by reduced brachial
artery flow-mediated dilation (FMD) to hyperemic stimuli [1,2].
Subjects in these studies consisted of college runners and endurance
athletes in Sweden; none were dancers. Several studies have shown
that ballet dancers have a high prevalence of amenorrhea [3–5] and
disordered eating [6–8]. Therefore this group also may be at high risk
for endothelial dysfunction.
Previous studies in athletes have shown a relationship between
estrogen levels and brachial artery FMD [9]. It is known that coronary
and peripheral vessels contain estrogen receptors, which allow
estrogen to play a regulatory role in vascular function. Estrogen
stimulates the production of nitric oxide (NO) through both genomic
and non-genomic effects, leading to increased production of
endothelial-derived NO, causing vasodilatation [10,11]. Estrogen
exerts long-term genomic effects via alteration of gene and protein
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expression, mostly at the level of gene transcription, resulting in
increased endothelial NO synthase (eNOS) synthesis and activity
[10,11]. In addition to these genomic effects, evidence supports acute
increases in eNOS via interaction with estrogen receptors on
endothelial cells [12]. Finally, amenorrhea associated with athletes is
known to have a steroid hormonal profile similar to that observed in
menopause. Therefore low estrogen levels, whether in a postmenopausal woman or a young athlete with athletic-associated
amenorrhea, will theoretically cause impaired endothelial cell function
and resultant impaired arterial dilation [1,2].
Abnormal endothelial dysfunction manifested as reduced
brachial artery dilation has been shown to have a positive predictive
value (95%) for coronary endothelial dysfunction [13]. In addition,
Schachinger and colleagues [14] have shown that coronary endothelial
vasodilator dysfunction predicts long-term atherosclerotic disease
progression and cardiovascular event rates. Woo and associates [15]
have shown that brachial endothelial dysfunction correlates with the
extent of coronary atherosclerosis. Therefore non-invasive assessment
of brachial endothelial function by high-frequency ultrasound can
provide valuable information about endothelial function in an otherwise
healthy athletic population.. Early treatment in this group is important
because cardiovascular disease is the number one cause of death in
women in the United States.
Rickenlund and colleagues [16] have shown that administration
of oral contraceptives (30 µg of ethinyl estradiol and 150 µg of
levonorgestrel) significantly improved brachial artery FMD in young
amenorrheic runners. However, the Women’s Health Initiative study
showed an increased risk of breast cancer, heart disease, stroke, and
blood clots among postmenopausal women who were using hormone
replacement therapy that included both estrogen and progestin
[17,18]. More recently, Chlebowski and colleagues [19] determined
that synthetic hormone replacement therapy increases breast cancer
risk and that these cancers tend to be more aggressive and lethal.
Although these findings have not been found in premenopausal
women, seeking an alternative treatment approach to reduced FMD in
young athletes is reasonable.

PM & R, Vol. 3, No. 11 (November 2011): pg. 1005-1012. DOI. This article is © Elsevier and permission has been granted
for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this article to be further
copied/distributed or hosted elsewhere without the express permission from Elsevier.

3

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

Folic acid has potential benefits with regard to cardiovascular
parameters such as endothelial function, arterial stiffness, blood
pressure, and thrombotic activity [20–28]. Several studies have
already shown that folic acid supplementation improves endothelial
function in various disease states, including hypercholesterolemia
[29,30], hypertension [28], diabetes [31], coronary artery disease
[32,33], and hyperhomocystinemia [15]. These studies suggest that
higher folic acid intake by specific populations may have
vasculoprotective effects.
Several mechanisms explain the effectiveness of folic acid
therapy. Folates are believed to participate in the endogenous
regeneration of tetrahydrobiopterin [34], an essential cofactor for
eNOS production of NO, and therefore may result in increased NO
production after supplementation. Folic acid has a known
homocysteine-lowering effect that could contribute to improvements in
endothelial function. In addition, folic acid may have a direct
antioxidant effect in the vasculature, increasing NO bioavailability,
which is a major factor influencing the improvement in FMD [13,32].
Therefore the purpose of this study was to determine if folic acid
supplementation of 10 mg per day would increase FMD in professional
dancers with reduced FMD.

Methods
Subjects and Experimental Design
This study was reviewed and approved by multi-institutional
human subjects internal review boards. Inclusion criteria included
professional female dancers, ages 18–35 years, from a single dance
company in the Midwest. Exclusion criteria included a history of heart
disease, vascular disease, hypertension, diabetes, hypercholesteremia,
chromosomal disorder, current pregnancy, pituitary tumor, oral
contraceptive use, anomalies of the reproductive system, and thyroid
disease. Any subject taking a cardiac, cholesterol, hypertension, or
thyroid medication was excluded from the study. Subjects were not
excluded based on ethnicity. Twenty-two women met the criteria and
completed the study. No women were excluded based on our criteria.
The study was explained in person, and informed consent was
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obtained. Medical history and menstrual status were obtained through
questionnaires and interview.

Serum Folic Acid Levels
Fasting whole serum folate levels were measured by the Bayer
ADVIA Centaur assay (Siemens Medical Solutions Diagnostics,
Deerfield, IL) before and after supplementation with folic acid. This
assay is a competitive immunoassay that uses direct chemiluminescent
technology. The inter-assay coefficient of variation was 5%–7%, the
intra-assay coefficient of variation was 4%–8%, the lower limit of
sensitivity was 0.35 ng/mL, and the upper limit of sensitivity was ≥24
ng/mL. Blood was drawn early in the morning after an overnight fast.
Subjects with FMD <5% were instructed to take folic acid (10 mg/day)
for 4 weeks. For standardization purposes, subjects were instructed to
take their supplements in the morning with food. Subjects kept written
logs and were randomly called to assess compliance.

Dietary History
Caloric micronutrient intake was determined from a prospective
3-day food diary recorded during 2 weekdays and 1 weekend day
during the dance training season. A registered research dietitian met
with each dancer for education and training in proportions or size of
food servings, proper recording of foods, and the use of the food diary
in general. Dietary analysis was performed by the research dietician
with use of Nutrition Data System for Research software version 2007
(developed by the Nutrition Coordinating Center, University of
Minnesota, Minneapolis, MN) to determine total calories; total
composition of fat, protein, and carbohydrates; and micronutrient
content (ie, folic acid, L-arginine, vitamin C, vitamin E, and vitamin
B12). Subjects were encouraged to weigh their food portions for
recording.

Menstrual Status
Self-administered questionnaires were used to determine
menarche, number of periods per year, number of days between
periods, skipped periods, history of thyroid disease or pituitary tumor,
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and use and type of birth control. A formal interview regarding
menstrual status and medical history was conducted by the principal
investigator. For the purpose of this study, eumenorrhea or regular
cycling was defined as menstrual bleeding every 28–30 days. Primary
amenorrhea was defined as absence of menarche by age 15 years and
secondary amenorrhea was defined as cessation of menses for >3
consecutive cycles after onset of menarche, excluding pregnancy.
Oligomenorrhea was represented by menstrual cycles with intervals
greater than 35 days for at least 12 months. Luteal phase dysfunction
was defined as a menstrual cycle less than 22 days. If subjects were
taking oral contraceptives for treatment of secondary amenorrhea,
they were identified as amenorrhea—oral contraceptive group. If they
were taking oral contraceptives for any other reason, they were
excluded from the study.

Cardiovascular Status
Brachial artery FMD and velocity were determined by techniques
previously used in this laboratory [1,35,36]. Subjects were studied in
a supine resting position following an 8-hour fast in a temperaturecontrolled room. Systemic arterial pressure was periodically monitored
in the nondominant arm with an automated sphygmomanometer.
Subjects were instrumented for continuous recording of
electrocardiogram, heart rate, and intermittent blood pressure. All
subjects were tested at approximately the same time of day, with
eumenorrheic, oligomenorrheic, and amenorrheic subjects studied in
the early follicular phase of the menstrual cycle (day 4–8) [37–39].
Amenorrheic subjects were tested randomly as schedules permitted,
but also in the early morning.

Statistics
Descriptive statistics are presented as mean ± standard
deviation (SD) for each measurement at baseline and after 4 weeks of
folic acid supplementation. The primary outcome of interest for this
study was change in brachial artery FMD before and after folic acid
supplementation. A paired t-test was used to compare FMD before and
after supplementation. All comparisons with the untreated group used
an unpaired t-test, whereas all pre-post comparisons used a paired t-
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test. Based on Box-Cox analysis, all nutritional intake values were log
transformed before the paired t-test. Because folic acid levels had an
upper quantification threshold at 24 ng/mL, a log-rank test was used
when comparing the folic acid levels (ng/mL) of the abnormal FMD
(5%) group (n = 14) with the normal FMD (>5%) group (n = 8)
before supplementation with folic acid. The mean and SD of the
underlying distribution were estimated by fitting a truncated normal
distribution. The pre-treatment and post-treatment folic acids levels
were compared using McNemar’s exact test on the indicator of
exceeding the 24 ng/mL threshold. All analyses were performed using
R software version 2.10.1 [40].

Results
Subject Characteristics
Twenty-two elite dancers consented to participate and
completed this study. Twenty dancers self-reported their ethnicity as
Caucasian, one reported Asian ethnicity, and one reported Hispanic
ethnicity, with an age of 23.2 ± 4.7 years (mean ± SD). Table 1
provides descriptive demographics of the cohort including height,
weight, percent body fat, body mass index, age, menarche, and years
dancing divided into 2 groups based on whether FMD was abnormal
(<5%) or normal (>5%). No difference in body mass index, percent
body fat, or menarche was found between the 2 groups. A difference
in age and years of dancing was found; the abnormal FMD group was
younger and had danced fewer total years compared with the normal
group.

PM & R, Vol. 3, No. 11 (November 2011): pg. 1005-1012. DOI. This article is © Elsevier and permission has been granted
for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this article to be further
copied/distributed or hosted elsewhere without the express permission from Elsevier.

7

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

Vascular Reactivity
Brachial artery data are summarized in Table 2 and Figure 1.
Table 2 includes data on heart rate (beats per minute), systolic arterial
pressure (mm Hg), diastolic arterial pressure (mm Hg), temperature
(°F), relative humidity (%), baseline brachial artery diameter (mm),
FMD (%), and peak change in flow velocity (%). Abnormal FMD was
defined by less than 5% dilation in response to an ischemic challenge
[35,36]. This definition is based on data from our laboratory (normal =
7.0% ± 1.5%; unpublished data) and others [41–43]. Subjects were
subsequently divided into a normal group (>5%, n = 8) and a reduced
group (<5%, n = 14). Brachial artery FMD was reduced in 14 of 22
dancers (64%). Baseline brachial diameters, arterial pressures, resting
heart rate, temperature, humidity, and peak change in flow velocity
were not significantly different (P > .05) between subjects with
reduced and normal FMD (Table 2). After folic acid supplementation of
10 mg/day for 4 weeks, all subjects had an increase in FMD (from
2.9% ± 1.5% to 7.1% ± 2.3%, P < .0001) (Figure 1). Individual data
for each subject before and after folic acid supplementation also is
provided (Figure 2).
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Figure 1. Fourteen dancers had reduced flow-mediated dilation (defined a priori as <
5%). Flow-mediated dilation increased after folic acid supplementation.
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Figure 2. Individual data of the 14 dancers with reduced flow-mediated dilation before
and after folic acid supplementation. FMD = flow-mediated dilation.

Serum Folic Acid Levels
No difference was found in serum folic acid between the
abnormal FMD group (<5%; n = 14; 19.2 ng/mL ± 5.3) and the
normal FMD group (>5%; n = 8; 17.3 ng/mL ± 5.0) prior to
supplementation (P = .37) (Figure 3). Folic acid levels increased in the
folic acid treatment group after supplementation, but the exact
amount is difficult to quantify because the highest value our laboratory
reports is 24.0 ng/mL; however, all post-treatment levels were above
the cut-off value of 24 ng/mL. In fact, the proportion of subjects above
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24 ng/mL increased significantly (21% versus 100%, P = .001 by
exact McNemar’s test) after supplementation (Figure 4).

Figure 3. Folic acid levels before supplementation at start of study between group
with normal flow-mediated dilation (N = 8) and reduced flow-mediated dilation (N =
14). FMD = flow-mediated dilation.
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Figure 4. Percentage of subjects who were above the laboratory threshold of 24
ng/mL before and after folic acid supplementation (10 mg/day for 4 weeks).

Dietary Intake
No difference was found in recorded dietary antioxidants
(vitamin C and vitamin E), folic acid, or L-arginine (co-factor eNOS),
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all which can affect NO levels. In addition, no differences in vitamin D,
vitamin B12, calories, protein, fat, or carbohydrates were found
between the abnormal FMD group and normal FMD group (P = .19) at
the start of the study (Table 3).

Amenorrhea/Oligomenorrhea
At the time of the study, 2 dancers were amenorrheic (9%) (2.0
± 0.1 years) and 6 dancers (27%) were oligomenorrheic (menstrual
cycles >35 days for at least 12 months). Collectively, 36% of 22
dancers self-reported current menstrual dysfunction, and they all had
an FMD of less than 5%. Three dancers (14%) were taking
contraceptive hormones because of a history of secondary
amenorrhea. The relationship between FMD and menstrual status is
reported in a previous study [9].

Discussion
The main finding from this study is that 64% (n = 14) of the
dancers in a professional dance company had evidence of abnormal
FMD and that FMD significantly improved with folic acid
supplementation (10 mg/day) for 4 weeks. The baseline FMD of this
group was 2.9%, and it improved to 7.1% after supplementation.
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Several studies in older men and women with chronic diseases have
shown an increase in FMD with folic acid supplementation [30,44,45].
However, this is the first study to reveal that folic acid
supplementation improves FMD in young professional dancers with
endothelial dysfunction.
These findings are consistent with a previous study in young
amenorrheic runners of similar age (mean ± SD, age 22.1 ± 4.8
years) with a similar reduction in FMD, who showed similar
improvement (3.0% to 7.7%) after folic acid supplementation (10
mg/day) for 4 weeks [35]. However, a significant methodological
difference exists between these two studies. In the previous study of
young amenorrheic women runners, altered menstrual status (ie,
amenorrhea) was the primary inclusion criteria for the study group. In
the present study of ballet dancers, the inclusion criteria for the
experimental group were dancers with reduced FMD (<5%) regardless
of menstrual status.
In the present study of ballet dancers, all subjects with reported
amenorrhea and oligomenorrhea had reduced FMD (<5%). Two of the
3 subjects were taking synthetic hormones for amenorrhea, and 4
eumenorrheic subjects had reduced FMD (<5%). Although abnormal
FMD in amenorrheic dancers is consistent with previous research [1,2],
the relationship between eumenorrhea and brachial artery FMD is not
as clear. A 2009 study [36] evaluated eumenorrheic runners and
brachial artery FMD. In this study, subjects were randomly assigned to
placebo or folic acid (10 mg/day; 4 weeks) in a blinded fashion. Folic
acid levels were measured before and after supplementation. Both
groups had normal folic acid levels at the start of the study. After the
supplementation period, the group taking folic acid had a significant
increase in folic acid levels, whereas there was no change in folic acid
levels in the placebo group. The group taking folic acid had a
significant increase (3%) in FMD compared with the placebo group
(0.11%), which had no increase. This finding is similar to that of the
current study of ballerinas, which showed an increase in FMD in 4
eumenorrheic subjects with an initial FMD <5%. However, the data in
eumenorrheic runners contradicts a 2010 study [35] which did not
show an increase in FMD in eumenorrheic runners, only in amenorrheic
runners, with folic acid supplementation. Possible explanations for the
discrepancy in brachial artery FMD in eumenorrheic runners is most
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likely multifactorial. The laboratory for these studies only reported an
upper threshold value of 24 ng/mL for serum folic acid levels. It may
be that the eumenorrheic group in the 2010 study had a significantly
lower folic acid level compared with the other studies. Aerobic fitness
is also known to affect FMD values, and this variable was not
measured in any of the studies. Finally, subjects may have incorrectly
reported eumenorrhea, but they could truly have anovulatory cycles
that could affect estrogen levels and FMD. Future studies with a larger
cohort with more precise measurement of serum folic acid and
estrogen levels are needed to further quantify the effect of folic acid in
eumenorrheic athletes.
The risk of toxicity from folic acid intake from supplements
and/or fortified foods is low [46]. Folic acid is a water-soluble vitamin
that is regularly eliminated in the urine. No adverse effects of folic acid
have been reported at 10 mg/day [15,46–49], and the Food and Drug
Administration MedWatch system does not list any adverse effects of
folic acid that apply to this study [47]. Higher doses (>20 mg/day) can
cause adverse effects such as upset stomach, sleep disturbances, and
skin problems. The recommended daily allowance for folate for women
ages 19–50 years is 400 µg/day, and the tolerable upper intake level
(UL) is 1 g/day. For women who have risk factors for neural tube
defects, 4 mg is recommended. It is important to recognize that the
upper intake level refers to the amount of synthetic folate (folic acid)
being consumed per day from fortified foods and/or supplements.
There is no health risk and no UL for natural sources of folate found in
food.
Despite the benefits of folic acid, some evidence indicates that
high levels of folic acid can pose a variety of health risks. High doses
of folic acid (>15 mg/day) can provoke seizures in patients taking
anticonvulsant medications [49]. None of our subjects had a known
seizure disorder. The National Institutes of Health [50] also states that
caution regarding supplementation with folic acid should be used in
patients with a vitamin B12 deficiency, because folic acid
supplementation may hide the deficiency and silently exacerbate the
condition. None of our subjects had low vitamin B12 levels as
determined by their 3-day food record.
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A recent study raises the possibility that folic acid
supplementation might increase the risk of colorectal adenoma in
patients with a known history of colorectal adenomas [51], but these
data have not been confirmed in prospective trials. In this study [51],
the rates of colon cancer recurrences were slightly higher at the first
and second colonoscopic follow-up (44.1% and 41.9%, respectively)
when compared with the placebo control group (42.4% and 37.2%,
respectively). This small observed increase may be related to more
widespread screening and better detection. The evidence linking folic
acid supplementation and an increase in colon cancer rates is
inconclusive and merits further investigation. Folic acid has not been
shown to directly cause colon cancer; however, if colon cancer is
present, folic acid may fuel its growth [51]. The risks of folic acid
supplementation are small and may be inconclusive with regard to
increased colon cancer risk. In many patient populations, the benefits
of folic acid supplementation likely outweigh the risks. From a clinical
perspective, it would seem logical that if FMD was determined to be
low, clinicians could potentially recommend folic acid on a daily basis
to athletes; however, length of time and optimal dosage is still to be
determined.

Study Limitations
These results must be interpreted in light of several limitations.
The small sample size and cross-sectional design are methodologic
shortcomings of this study. In addition, because of the inability of our
laboratories to quantify serum folic acid above 24 ng/mL, true folic
acid levels were unknown. Finally, aerobic fitness was not determined,
which is known to affect FMD. Future studies should include a larger
cohort, with precise folic acid measurements in addition to metabolic
testing.

Conclusion
In summary, this study showed that folic acid supplementation
(10 mg/day for 4 weeks) significantly improved brachial artery FMD in
professional dancers with reduced FMD. This finding may have clinical
importance because reduced FMD is an accepted early sign of
accelerated development of atherosclerosis, which may have an
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adverse health impact in this asymptomatic population of athletic
professionals. Further studies should test this hypothesis in a larger
cohort of dancers with and without endothelial dysfunction.
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